huahaipharm(SH:600521) Xin Lang Cai Jing·2025-07-31 09:18Core Viewpoint - Huahai Pharmaceutical (600521.SH) announced that its subsidiaries Huao Tai and Huabo Biotech received approval from the National Medical Products Administration for the clinical trial of injectable HB0043, a bispecific antibody targeting IL-17A and IL-36R, aimed at treating various autoimmune diseases [1] Summary by Relevant Categories Product Development - HB0043 is a recombinant humanized IgG1 bispecific antibody with high binding and blocking activity [1] - The company has invested approximately 69.09 million yuan in the research and development of this project [1] Market and Competition - The development cycle for pharmaceutical products is long and carries uncertainties [1] - Future competitive dynamics in the market are expected to change [1]